Osimertinib mesylate Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Osimertinib is active against exon 19 deletions, exon 21 mutations, and also the exon 20 T790M mutations. It is preferentially selective for mutated EGFR, and therefore toxicity at therapeutic doses is lower than for first- and second-generation agents. Notably, osimertinib is able to cross the blood-brain barrier, making it active against disease in the CNS.

Indications

The collection of ibrutinib (Imbruvica(R), Pharmacyclics Inc.), afatinib, and osimertinib represents the small, yet expanding, group of covalent SMKIs. Ibrutinib is a non-receptor Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed chronic lymphocytic leukemia. Afatinib, approved for NSCLC in 2013 and squamous NSCLC in 2016, is a second-generation irreversible EGFR inhibitor that targets wild-type EGFR, the mutant T790M EGFR, and HER2. Osimertinib (AZD9291), which was approved by FDA in November 2015, is a third-generation irreversible EGFR inhibitor that selectively targets the mutant T790M EGFR. Rociletinib, which shares a high degree of structural similarity with that of osimertinib, is a promising covalent EGFR inhibitor developed by Clovis Oncology aimed for the treatment of patients with EGFR T790M-mutated NSCLC, until the company terminated its development in May 2016 following a negative vote fromthe FDA’sOncologic Drugs Advisory Committee.

Definition

ChEBI: A methanesulfonate (mesylate) salt prepared from equimolar amounts of osimertinib and methanesulfonic acid. Used for treatment of EGFR T790M mutation positive non-small cell lung cancer.

Application

Osimertinib mesylate is approved to treat: Non-small cell lung cancer that has certain EGFR gene mutations. It is used in adults: As adjuvant therapy after surgery to remove the cancer; As the first therapy for cancer that has spread to other parts of the body, or in patients whose cancer has spread to other parts of the body and got worse during or after treatment with another EGFR tyrosine kinase inhibitor.

Trademarks

Tagrisso^TM

Nebenwirkungen

Osimertinib toxicity is dose-dependent and is associated with fewer gastrointestinal and dermatologic adverse events than with other approved EGFR TKIs.

Osimertinib mesylate Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Osimertinib mesylate Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.	+86-0531-69954981 +8615666777973	dwyane.wang@boyuanpharm.com	China	211	58
Hebei Chuanghai Biotechnology Co,.LTD	+86-13131129325	sales1@chuanghaibio.com	China	5889	58
Henan Bao Enluo International TradeCo.，LTD	+86-17331933971 +86-17331933971	deasea125996@gmail.com	China	2472	58
Shaanxi Haibo Biotechnology Co., Ltd	+undefined18602966907	qinhe02@xaltbio.com	China	997	58
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	info@fdachem.com	China	20267	58
Apeloa production Co.,Limited	+8619933239880	admin@apcl.com.cn	China	861	58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	+86-18600796368 +86-18600796368	sales@sjar-tech.com	China	484	58
S&Y Biochem Co.,Ltd	+8617774091612	marketing@sybiochem.com	China	128	58
Capot Chemical Co.,Ltd.	+86-（0）57185586718 +86-13336195806	sales@capot.com	China	29793	60
Shanghai Daken Advanced Materials Co.,Ltd	+86-371-66670886	info@dakenam.com	China	18940	58

---

• AZD-9291 (Mesylate)
• AZD-9291 mesylate N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1)
• Osimertinib Mesylate(AZD9291)
• Osimertinib mesylate
• Mereletinib Ms salt
• AZD9291 Ms salt, Osimertinib Ms salt
• N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate
• AZD-9291 MESYLATE(OSIMERTINIB)
• N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate
• Mereletinib mesylate, 98%, a potent and selective mutated forms EGFR inhibitor
• AZD-9291 (MESYLATE);TAGRISSO;OSIMERTINIB MESYLATE
• AZD-9291 mesylate (Osimertinib mesylate
• AZD-9291 mesylate (Osimertinib,Mereletinib)
• MERELETINIB MESYLATE; EGFR INHIBITOR; AZD9291 MESYLATE; AZD 9291 MESYLATE;TAGRISSO
• Mesylate-AZD9291
• Osimertinib Mesylate (Tagrisso, Mereletinib, AZD-9291)
• N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate(AZD9291 mesylate)
• Osimertinib Impurity 30
• Mereletinib mesylateQ: What is Mereletinib mesylate Q: What is the CAS Number of Mereletinib mesylate Q: What is the storage condition of Mereletinib mesylate Q: What are the applications of Mereletinib mesylate
• Mereletinib mesylate
• N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide methanesulfonate
• N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide methanesulfonate (1:1)
• Osimertinib
• Tagrisso
• N-[2-(2-dimethylaminoethylmethylamino)-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide mesylate salt
• Osimertinib d6
• Osimertinib methanesulfonate
• Osimertinib (AZD9291) mesylate
• Undecanoicacid,15-hydroxy-
• 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1)
• Osimertinib mesylate (AZD-9291 mesylate)
• N-2-2-(Dimethylamino)ethylmethylamino-4-methoxy-5-4-(1-methyl-1H-indol-3-yl)-pyrimidin-2-ylaminophenyl-acrylamide methanesulfonate (1:1)
• Osimertinib Mesylate API
• Osimeitinib mesylate
• osimertinib MsOH
• PB1211
• Osimertinib mesylate, 10 mM in DMSO
• 1421373-66-1
• 421373-66-1
• C28H33N7O2CH4O3S
• C29H37N7O5S
• AZD09
• API
• 1421373-66-1